Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- HER2-positive Breast Cancer, Her 2 Positive Breast Cancer
- Main trialPhase 3
- “Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy”In the company’s words, NCT06968585 on ClinicalTrials.gov
Other drugs for HER2-positive Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up2
- 30 NovPhase 3 trial completes · ClinicalTrials.gov
- 20 Sep 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Nov 2026 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | |
| Phase 2Recruiting | 20 Sep 2027 | A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | |
| Phase 1/2Completed | 12 Jan 2022 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | |
| Phase 1Completed | 9 Apr 2026 | A Study of A166 in Patients With Advanced Solid Malignant Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026